Phase 2
Completed N=9
Improving Ventilatory Capacity in Those With Chronic High Level SCI
Spinal Cord Injuries
Source: ClinicalTrials.gov NCT05041322 ↗
Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcomePrimary: Pulmonary Function — 3.59; 3.77 L
Summary
The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pulmonary Function |
3.59; 3.77 | — |
| PRIMARY Hypercapnic Ventilatory Response |
0.659; 0.566 | — |
| PRIMARY Sleep Quality |
4.26; 6.18 | — |
| PRIMARY Exercise Pulmonary Capacity |
18.28; 17.69 | — |
Eligibility Criteria
Inclusion Criteria
- Chronic high-level SCI (at least 24-months post injury)
- Age 18 to 50 years.
- Medically stable
- Spinal Cord Injury ≥T3
- American Spinal Injury Association grade A or B or C.
- Able to perform arm crank exercise.
Exclusion Criteria
- Cardiomyopathy
- High blood pressure( >140/90 mmHg or you are taking high blood pressure medication)
- Significant irregular heartbeat
- Heart disease
- Chronic lung disease (COPD, bronchitis)
- Current use of cardioactive or antidepressant drugs
- Family history of significant irregular heart beat or sudden cardiac death
- Orthostatic hypotension (symptomatic fall in blood pressure >30 mmHg when upright)
- Current grade 2 or greater pressure ulcers at relevant contact site
- Neurological disease (stroke, peripheral neuropathy, myopathy)
- Arm or shoulder conditions that limit ability to perform arm crank exercise
- History of bleeding disorder, diabetes, kidney disease, cancer, other neurological disease
- Recent weigh change (greater than 10 pounds)
- Regular use of tobacco
- Intrathecal baclofen pump,
- Current use of cardioactive, antidepressant, other sedating agents
- Suicidal ideation
- Pregnant and/or breastfeeding women.
In addition, subjects must have no known hypersensitivity to Buspar and must not be taking a monoamine oxidase inhibitor.
Data sourced from ClinicalTrials.gov (NCT05041322). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.